FDA clears GE's PET/CT quantitative imaging technology

GE Healthcare has received FDA clearance of Q.Freeze, a PET/CT quantitative imaging technology designed for treatment evaluation earlier in a patient’s cancer treatment.

Q.Freeze combines the quantitative benefits of 4D phase-matched PET/CT imaging, MotionMatch, into one static image, according to the Waukesha, Wis.-based company. Q.Freeze is included in GE Healthcare's Q.Suite, a collection of features designed to provide consistent standardized uptake value (SUV) readings, and which does not have CE Mark approval.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.